Total Funding
65
61
Total FundingSeries A raised
Growth Score
-13 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
9022
Gilgamesh Pharmaceuticals is a clinical-stage biotechnology company that develops psychedelic and related drugs to treat mental illnesses.
- Jonathan Sporn: Chief Executive Officer and Chairman of the Board of DirectorsPast Role: Gilgamesh Pharmaceuticals, CEO & Co-Founder
Mike Cunningham: Co-Founder
About the Company
Gilgamesh Pharmaceuticals focuses on developing therapeutics that target neuropsychiatric and central nervous system conditions using small molecules derived from research on psychedelic compounds. The company designs and tests compounds that aim to modulate brain pathways involved in mental health disorders while reducing hallucinogenic effects.
Its pipeline includes drug candidates intended for conditions such as depression, anxiety, and substance use disorders. Gilgamesh Pharmaceuticals conducts preclinical and clinical studies to evaluate the safety, dosing, and efficacy of its compounds. The company integrates medicinal chemistry, neuroscience, and clinical research to support drug development and regulatory progression.
